Our study fosters the evaluation of the S100A9 inhibitor tasquinimod, already in clinical trial for the treatment of relapsed/refractory multiple myeloma patients, in AML, as a single agent or in combination with venetoclax. The gene discussed is S100A9; the disease is plasma cell myeloma.